Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

DNA Tests in Detecting Disseminated Disease in Tumor, Blood, and Bone Marrow Samples From Patients With Rhabdomyosarcoma

This study has been completed.
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Children's Oncology Group Identifier:
First received: August 17, 2011
Last updated: May 13, 2016
Last verified: May 2016

RATIONALE: DNA analysis of tumor, blood, and bone marrow may help doctors predict if the disease has been disseminated.

PURPOSE: This research trial studies DNA tests in detecting disseminated disease in tumor, blood, and bone marrow samples from patients with rhabdomyosarcoma.

Condition Intervention
Genetic: DNA methylation analysis
Genetic: microarray analysis
Genetic: polymerase chain reaction
Other: laboratory biomarker analysis

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Retrospective
Official Title: DNA Methylation-based Assays for Detecting Disease Spread in Rhabdomyosarcoma

Resource links provided by NLM:

Further study details as provided by Children's Oncology Group:

Primary Outcome Measures:
  • Panel of hypermethylation assays for minimal disseminated RMS
  • Detection of RMS cells in bone marrow

Biospecimen Retention:   Samples With DNA
Tumor, Blood, and Bone Marrow Samples

Estimated Enrollment: 170
Study Start Date: August 2011
Study Completion Date: May 2016
Primary Completion Date: May 2016 (Final data collection date for primary outcome measure)
Detailed Description:


  • To establish a panel of hypermethylation assays for minimal disseminated disease analysis in rhabdomyosarcoma (RMS).
  • To apply the hypermethylation assays to a series of bone marrow specimens from RMS patients.

OUTLINE: Archived tumor, bone marrow, and peripheral blood samples are analyzed for DNA hypermethylation by PCR-based assays and microarray assays. Results are then compared with each patient's clinical and pathological characteristics, and outcomes. Patterns of locus hypermethylation in tumor and paired bone marrow samples are also compared.


Ages Eligible for Study:   up to 18 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Diagnosed with rhabdomyosarcoma


  • Diagnosed with rhabdomyosarcoma (RMS)
  • Tumor, bone marrow, and peripheral blood samples from the Children's Oncology Group D9803 trial of intermediate-risk RMS


  • Not specified


  • Not specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01419509

Sponsors and Collaborators
Children's Oncology Group
National Cancer Institute (NCI)
Principal Investigator: Stephen R. Master, MD University of Pennsylvania
  More Information

Responsible Party: Children's Oncology Group Identifier: NCT01419509     History of Changes
Other Study ID Numbers: ARST11B1
COG-ARST11B1 ( Other Identifier: Children's Oncology Group )
ARST11B1 ( Other Identifier: Children's Oncology Group )
NCI-2011-02985 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
Study First Received: August 17, 2011
Last Updated: May 13, 2016

Keywords provided by Children's Oncology Group:
alveolar childhood rhabdomyosarcoma
embryonal childhood rhabdomyosarcoma
embryonal-botryoid childhood rhabdomyosarcoma
mixed childhood rhabdomyosarcoma
pleomorphic childhood rhabdomyosarcoma
previously untreated childhood rhabdomyosarcoma
nonmetastatic childhood soft tissue sarcoma

Additional relevant MeSH terms:
Neoplasms, Connective and Soft Tissue
Neoplasms by Histologic Type
Neoplasms, Muscle Tissue processed this record on May 25, 2017